Novo Nordisk: Wegovy prices in US fell slightly in Q1

Novo Nordisk NOVO_B has seen the price of its hugely popular weight-loss drug Wegovy fall in the United States as volumes and competition have increased, and it expects that to continue through the year, a senior executive said on Thursday.

Wegovy prices in the United States were "slightly down" in the first quarter, Chief Financial Officer Karsten Munk Knudsen said on a call with media.

The comments came after the Danish drugmaker raised its full-year outlook due to explosive demand for the weekly injection.